# A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)

> **NCT00746694** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 154 (actual)

## Conditions studied

- Ovarian Neoplasms
- Breast Neoplasms
- Paresthesia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00746694
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2015-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00746694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00746694, "A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT00746694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*